公开(公告)号：US12194154B2

公开(公告)日：2025-01-14

申请号：US17437249

申请日：2020-03-12

Applicant: RIKEN

Inventor： Hiroyoshi Aoki ,  Yutaka Yamagata ,  Moriya Ohkuma ,  Masahiro Yuki

IPC: A61K9/50 ,  A61K31/711 ,  A61K35/66

Abstract: A method for producing a capsule, including cooling a suspension so as to gel a thermoresponsive polymer including a core 8 formed from a gel of an ionically-bonded polymer and form a shell (17) of a hydrogel, the suspension being obtained by suspending, in oil (10), a sol (9) of the thermoresponsive polymer, and then using a chelating agent to solate the core so as to hollow out the inside.

公开(公告)号：US20240279308A1

公开(公告)日：2024-08-22

申请号：US18581947

申请日：2024-02-20

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Dominik MAURER ,  Sebastian BUNK ,  Leonie ALTEN

IPC: C07K14/725 ,  A61K35/12 ,  A61K35/17 ,  A61K35/66 ,  A61K38/00 ,  C07K14/435 ,  C12N15/09 ,  C12N15/10

CPC classification number: C07K14/7051 ,  A61K35/12 ,  A61K35/17 ,  A61K35/66 ,  C07K14/435 ,  C12N15/09 ,  C12N15/10 ,  A61K38/00

Abstract: Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tmor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240150798A1

公开(公告)日：2024-05-09

申请号：US18482834

申请日：2023-10-06

Applicant: Genomatica, Inc.

Inventor： Benjamin ADELSTEIN ,  Robin E. OSTERHOUT ,  Mark J. BURK

IPC: C12P7/62 ,  A23L33/135 ,  A61K31/22 ,  A61K35/66 ,  A61K36/064 ,  C07C69/675 ,  C12N1/00 ,  C12N1/14 ,  C12N1/20 ,  C12N9/18 ,  C12N15/52

CPC classification number: C12P7/62 ,  A23L33/135 ,  A61K31/22 ,  A61K35/66 ,  A61K36/064 ,  C07C69/675 ,  C12N1/00 ,  C12N1/145 ,  C12N1/205 ,  C12N9/18 ,  C12N15/52 ,  C12Y101/01035 ,  C12Y101/011 ,  C12Y301/01067 ,  C12Y301/08001 ,  C07B2200/05 ,  C12R2001/00 ,  Y02P20/10

Abstract: Provided herein are non-naturally occurring microbial organisms having a pathway for production of (3R)-hydroxybutyl (3R)-hydroxybutyrate, wherein the organism can further include a (R)-1,3-butanediol pathway, a (3R)-hydroxybutyrate pathway, a (3R)-hydroxybutyryl-CoA pathway, an acetoacetate pathway, an acetoacetyl-CoA pathway, a (3R)-hydroxybutyl-ACP pathway, or an acetoacetyl-ACP pathway. Additionally provided are methods and processes for producing and isolating (3R)-hydroxybutyl (3R)-hydroxybutyrate using the microbial organisms, and various compositions having the (3R)-hydroxybutyl (3R)-hydroxybutyrate. Still further provided are methods of treating or preventing a disease, disorder or condition using the (3R)-hydroxybutyl (3R)-hydroxybutyrate produced by the microbial organisms of the invention.

公开(公告)号：US11951138B2

公开(公告)日：2024-04-09

申请号：US14773887

申请日：2014-03-13

Applicant: The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center)

Inventor： Itzhak Mizrahi ,  Elie Jami

IPC: A61K35/74 ,  A23K10/18 ,  A23K20/195 ,  A23K50/10 ,  A23K50/60 ,  A61K35/66 ,  C12N1/20 ,  C12Q1/6869 ,  C12Q1/689

CPC classification number: A61K35/74 ,  A23K10/18 ,  A23K20/195 ,  A23K50/10 ,  A23K50/60 ,  A61K35/66 ,  C12N1/20 ,  C12Q1/6869 ,  C12Q1/689 ,  C12Q2600/124

Abstract: A method of mimicking a phenotype of a first ruminating animal in a second ruminating animal is disclosed. The method comprises administering to the second ruminating animal a microbial composition comprising a plurality of microbes having a signature which is statistically significantly similar to the microbial signature of a rumen microbiome of the first ruminating animal, wherein the first and the second ruminating animal are of identical species, thereby mimicking the phenotype of the first ruminating animal in the second ruminating animal.

公开(公告)号：US11945854B2

公开(公告)日：2024-04-02

申请号：US17125922

申请日：2020-12-17

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Dominik Maurer ,  Sebastian Bunk ,  Leonie Alten

IPC: C07K14/725 ,  A61K35/12 ,  A61K35/17 ,  A61K35/66 ,  C07K14/435 ,  C12N15/09 ,  C12N15/10 ,  A61K38/00

CPC classification number: C07K14/7051 ,  A61K35/12 ,  A61K35/17 ,  A61K35/66 ,  C07K14/435 ,  C12N15/09 ,  C12N15/10 ,  A61K38/00

Abstract: Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240041944A1

公开(公告)日：2024-02-08

申请号：US18181504

申请日：2023-03-09

Applicant: ISOThrive LLC

Inventor： Lee Madsen, II ,  Jack Oswald ,  Sarah Stanley

IPC: A61K35/66 ,  A61K31/702 ,  A61K31/732 ,  A61K31/733 ,  A61P1/00 ,  A61P3/00 ,  A61P35/00 ,  A61P5/00 ,  C12Q1/689 ,  A61K35/744 ,  A61K31/717 ,  A61K31/715 ,  A61K31/718 ,  A61K31/736 ,  C12Q1/04 ,  C12Q1/68

CPC classification number: A61K35/66 ,  A61K31/702 ,  A61K31/732 ,  A61K31/733 ,  A61P1/00 ,  A61P3/00 ,  A61P35/00 ,  A61P5/00 ,  C12Q1/689 ,  A61K35/744 ,  A61K31/717 ,  A61K31/715 ,  A61K31/718 ,  A61K31/736 ,  C12Q1/04 ,  C12Q1/68

Abstract: Methods are described herein for identifying and providing prebiotic compositions that are optimized for the health needs of individuals.

公开(公告)号：US11814664B2

公开(公告)日：2023-11-14

申请号：US14893510

申请日：2014-05-23

Applicant: Genomatica, Inc.

Inventor： Benjamin Adelstein ,  Robin E. Osterhout ,  Mark J. Burk

IPC: C12P7/62 ,  C12N9/18 ,  A61K31/22 ,  A61K35/66 ,  A61K36/064 ,  A23L33/135 ,  C12N1/00 ,  C12N1/14 ,  C12N1/20 ,  C07C69/675 ,  C12N15/52 ,  C12R1/00 ,  C12R1/01 ,  C12R1/645

CPC classification number: C12P7/62 ,  A23L33/135 ,  A61K31/22 ,  A61K35/66 ,  A61K36/064 ,  C07C69/675 ,  C12N1/00 ,  C12N1/145 ,  C12N1/205 ,  C12N9/18 ,  C12N15/52 ,  C12Y101/011 ,  C12Y101/01035 ,  C12Y301/01067 ,  C12Y301/08001 ,  A23V2002/00 ,  C07B2200/05 ,  C12R2001/00 ,  C12R2001/01 ,  C12R2001/645 ,  Y02P20/10

Abstract: Provided herein are non-naturally occurring microbial organisms having a pathway for production of (3R)-hydroxybutyl (3R)-hydroxybutyrate, wherein the organism can further include a (R)-1,3-butanediol pathway, a (3R)-hydroxybutyrate pathway, a (3R)-hydroxybutyryl-CoA pathway, an acetoacetate pathway, an acetoacetyl-CoA pathway, a (3R)-hydroxybutyl-ACP pathway, or an acetoacetyl-ACP pathway. Additionally provided are methods and processes for producing and isolating (3R)-hydroxybutyl (3R)-hydroxybutyrate using the microbial organisms, and various compositions having the (3R)-hydroxybutyl (3R)-hydroxybutyrate. Still further provided are methods of treating or preventing a disease, disorder or condition using the (3R)-hydroxybutyl (3R)-hydroxybutyrate produced by the microbial organisms of the invention.

公开(公告)号：US11707518B2

公开(公告)日：2023-07-25

申请号：US17699055

申请日：2022-03-18

Applicant: Gholam A. Peyman

Inventor： Gholam A. Peyman

IPC: A61K39/215 ,  A61K31/155 ,  A61K31/422 ,  A61K31/506 ,  A61K39/39 ,  A61K39/395 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  A61K35/13 ,  A61K35/66 ,  A61K35/74 ,  A61K35/76 ,  A61K36/06 ,  A61K39/00 ,  C12N1/00 ,  C12N1/02

CPC classification number: A61K39/215 ,  A61K31/155 ,  A61K31/422 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K35/13 ,  A61K35/66 ,  A61K35/74 ,  A61K35/76 ,  A61K36/06 ,  A61K39/00 ,  A61K39/39 ,  A61K39/3955 ,  A61K45/06 ,  C12N1/00 ,  C12N1/02 ,  A61K2039/543 ,  A61K2039/55511 ,  C12N2501/999

Abstract: A therapeutic vaccination method includes growing and harvesting viruses, bacteria, fungi, parasites, or tumor cells on a cell culture or other appropriate medium; killing the viruses, bacteria, fungi, parasites, or tumor cells in the cell culture or other appropriate medium with a dose of methylene blue; separating the dead viruses, bacteria, fungi, parasites, or tumor cells from a remainder of the cell culture or other appropriate medium using a filter and/or centrifuge; adding antivirals, antibacterials, antifungals, antiparasitics, and/or anti-neoplastic medications at non-toxic therapeutic concentrations to the dead viruses, bacteria, fungi, parasites, or tumor cells so as to form a therapeutic vaccine; and administering the therapeutic vaccine to a patient in need thereof to simultaneously produces a therapeutic response and a humoral and cellular immune response in the body of the patient without resulting in deleterious side effects to the patient.

公开(公告)号：US11319279B2

公开(公告)日：2022-05-03

申请号：US17092949

申请日：2020-11-09

Applicant: Korea Research Institute of Bioscience and Biotechnology

Inventor： Won Gon Kim ,  Hyun Ju Kim ,  Yu Jin Kim ,  Kyung Yun Cho

IPC: C07C235/64 ,  C07C233/75 ,  C07C235/56 ,  C07C237/42 ,  A61K31/166 ,  A61K31/135 ,  A61K45/06 ,  A61K35/66

Abstract: The present invention relates to: coralmycin A and B, which are novel compounds exhibiting antimicrobial activity, an isomer thereof, a derivative thereof or a pharmaceutically acceptable salt thereof; a microorganism of the genus Corallococcus producing the same; and an antimicrobial use thereof.
The coralmycin A and B have very strong antimicrobial activity against antibiotic-resistant bacteria such as MRSA, QRSA, VRE, VISA, etc.; Acinetobacter baumannii, which is a multidrug-resistant microorganism; and also against gram-positive microorganisms and gram-negative microorganisms. Therefore, the present invention can be very useful for prevention, treatment and alleviation of various microbial infections, and thus can be widely applied to the medical supply, quasi-drug, food, and feed industries.

公开(公告)号：US11103539B2

公开(公告)日：2021-08-31

申请号：US16443501

申请日：2019-06-17

Applicant: GI BIOME

Inventor： Mi Na Kweon ,  Jin Young Yang

IPC: A61K35/74 ,  A61K38/17 ,  A61K35/66 ,  A23L33/00 ,  A23L33/135 ,  A61K45/06 ,  C12N5/0784

Abstract: The present disclosure relates to a composition for preventing or treating metabolic diseases, in which the composition includes Bacteroides acidifaciens as an active ingredient. In addition, the present disclosure relates to a composition for oxidizing fat or inhibiting DPP-4, in which the composition includes Bacteroides acidifaciens as an active ingredient. In addition, the present disclosure relates to a transformant expressing a lean phenotype, in which an Atg7 gene is deleted in dendritic cells.